

DAFTAR PUSTAKA

- Al-Ardhi, F.M., Novotny, L., Alhunayan, A., dan Al-Tannak, N.F., 2022. Comparison of remdesivir and favipiravir - the anti-Covid-19 agents mimicking purine RNA constituents. *Biomedical Papers*, **166**: 12–20.
- Azer, S.A., 2020. 'COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics | Elsevier Enhanced Reader', . URL: <https://reader.elsevier.com/reader/sd/pii/S2052297520300901?token=8839769A60D1557A3D5F1A76541CE75927E45CE3909B5696DEFEE776386525ACDB6853E8FBC876F1E7B6135DE9DA7749&originRegion=eu-west-1&originCreation=20220417153735> (diakses tanggal 17/4/2022).
- Azka, L., Medison, I., dan Mizarti, D., 2021. Antiviral Therapy in Corona Virus Disease-19 (Covid-19). *Biomedical Journal of Indonesia*, **7**: 451–462.
- Beigel, J.H., 2021. What is the role of remdesivir in patients with COVID-19? *Current Opinion in Critical Care*, **27**: 487–492.
- Beigel, J.H., Tomashek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S., Kalil, A.C., dkk., 2020. Remdesivir for the Treatment of Covid-19 — Final Report. *New England Journal of Medicine*, **383**: 1813–1826.
- Burhan, E., Susanto, A.D., Nasution, S.A., Ginanjar, E., Pitoyo, W., Susilo, A., dkk., 2022. Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia 176.
- Cai, Qingxian, Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., dkk., 2020. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. *Engineering (Beijing, China)*, **6**: 1192–1198.
- Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S.C., dan Di Napoli, R., 2022. Features, Evaluation, and Treatment of Coronavirus (COVID-19), dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- CDC, 2020. 'Cases, Data, and Surveillance', *Centers for Disease Control and Prevention*. URL: <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html> (diakses tanggal 2/4/2023).
- CDC, 2022. 'COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022', . National Center for Emerging and Zoonotic Infectious Diseases.
- Chakraborty, A. dan Diwan, A., 2020. Pharmacodynamics of Remdesivir: How to Improve for COVID-19 Treatment. *Journal of Biomedical Research & Environmental Sciences*, **1**: 431–438.
- Cheng, N.M., Chan, Y.C., dan Cheng, S.W., 2022. COVID-19 related thrombosis: A mini-review. *Phlebology*, **37**: 326–337.

- Cordon-Cardo, C., Pujadas, E., Wajnberg, A., Sebra, R., Patel, G., Firpo-Betancourt, A., dkk., 2020. COVID-19: Staging of a New Disease. *Cancer Cell*, **38**: 594–597.
- COVID-19 Treatment Guidelines Panel, 2021. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines 393.
- Cui, Y., Sun, Y., Sun, J., Liang, H., Ding, X., Sun, X., dkk., 2021. Efficacy and Safety of Corticosteroid Use in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis. *Infectious Diseases and Therapy*, **10**: 2447–2463.
- Dahlan, M.S., 2012. *Analisis Multivariat Regresi Logistik*, 2nd ed. PT Epidemiologi Indonesia, Jakarta.
- Damayanti, H., Sajinadiyasa, I.G.K., Risni, H.W., dan Sauriasari, R., 2021. The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia. *Kesmas: Jurnal Kesehatan Masyarakat Nasional (National Public Health Journal)*, **16**: .
- Duo, H., Li, Y., Sun, Y., Wei, L., Wang, Z., Fang, F., dkk., 2022. Effect of therapeutic versus prophylactic anticoagulation therapy on clinical outcomes in COVID-19 patients: a systematic review with an updated meta-analysis. *Thrombosis Journal*, **20**: 47.
- Eastman, R.T., Roth, J.S., Brimacombe, K.R., Simeonov, A., Shen, M., Patnaik, S., dkk., 2020. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. *ACS Central Science*, **6**: 672–683.
- Ghasemnejad-Berenji, M. dan Pashapour, S., 2021. Favipiravir and COVID-19: A Simplified Summary. *Drug Research*, **71**: 166–170.
- Goldman, J.D., Lye, D.C.B., Hui, D.S., Marks, K.M., Bruno, R., Montejano, R., dkk., 2020. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. *New England Journal of Medicine*, **383**: 1827–1837.
- Granata, G., Schiavone, F., Pipitone, G., Taglietti, F., dan Petrosillo, N., 2022. Antibiotics Use in COVID-19 Patients: A Systematic Literature Review. *Journal of Clinical Medicine*, **11**: 7207.
- Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., dkk., 2020. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA*, **323**: 1574–1581.
- Groban, L., Wang, H., Sun, X., Ahmad, S., dan Ferrario, C.M., 2020. Is Sex a Determinant of COVID-19 Infection? Truth or Myth? *Current Hypertension Reports*, **22**: 62.
- Guo, W., Li, M., Dong, Y., Zhou, H., Zhang, Z., Tian, C., dkk., 2020. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes/Metabolism Research and Reviews*, **36**: e3319.
- He, F., Deng, Y., dan Li, W., 2020. Coronavirus disease 2019: What we know? *Journal of*

Medical Virology, **92**: 719–725.

- Henry, B.M. dan Lippi, G., 2020. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. *International Urology and Nephrology*, **52**: 1193–1194.
- Humeniuk, R., Mathias, A., Kirby, B.J., Lutz, J.D., Cao, H., Osinusi, A., dkk., 2021. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. *Clinical Pharmacokinetics*, **60**: 569–583.
- Ivashchenko, A.A., Dmitriev, K.A., Vostokova, N.V., Azarova, V.N., Blinow, A.A., Egorova, A.N., dkk., 2020. AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, **73**: 531–534.
- Jomah, S., Asdaq, S.M.B., dan Al-Yamani, M.J., 2020. 'Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review | Elsevier Enhanced Reader', . URL: <https://reader.elsevier.com/reader/sd/pii/S1876034120305931?token=491720BCBD5AB5712833685C8EB4BE10A1FE536D87452993B1B0857DE1B101A19E7A8649EFBAB2EA56058D154B70548F&originRegion=eu-west-1&originCreation=20220322084213> (diakses tanggal 22/3/2022).
- Joshi, S., Parkar, J., Ansari, A., Vora, A., Talwar, D., Tiwaskar, M., dkk., 2021. Role of favipiravir in the treatment of COVID-19. *International Journal of Infectious Diseases*, **102**: 501–508.
- Kemenkes RI, 2022. 'Peta Sebaran', *covid19.go.id*. URL: <https://covid19.go.id/peta-sebaran> (diakses tanggal 22/3/2022).
- Kollias, A., Kyriakoulis, K.G., Dimakakos, E., Poulakou, G., Stergiou, G.S., dan Syrigos, K., 2020. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. *British Journal of Haematology*, **189**: 846–847.
- Law, M.F., Ho, R., Law, K.W.T., dan Cheung, C.K.M., 2021. Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases. *World Journal of Hepatology*, **13**: 1850–1874.
- Li, G., Chen, Z., Lv, Z., Li, H., Chang, D., dan Lu, J., 2021. Diabetes Mellitus and COVID-19: Associations and Possible Mechanisms. *International Journal of Endocrinology*, **2021**: 1–10.
- Li, H., Yan, B., Gao, R., Ren, J., dan Yang, J., 2021. Effectiveness of corticosteroids to treat severe COVID-19: A systematic review and meta-analysis of prospective studies. *International Immunopharmacology*, **100**: 108121.
- Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., dkk., 2020. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *New England Journal of Medicine*, **382**: 1199–1207.

- Liu, J., Zheng, X., Tong, Q., Li, W., Wang, B., Sutter, K., dkk., 2020. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. *Journal of Medical Virology*, **92**: 491–494.
- Mahajan, L., Singh, A.P., dan Gifty, 2021. Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study. *Indian Journal of Anaesthesia*, **65**: S41–S46.
- Marra, F., Smolders, E.J., El-Sherif, O., Boyle, A., Davidson, K., Sommerville, A.J., dkk., 2021. Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. *Drugs in R&D*, **21**: 9–27.
- Oliver, M.E. dan Hinks, T.S.C., 2021. Azithromycin in viral infections. *Reviews in Medical Virology*, **31**: e2163.
- Ortigoza, M.B., Yoon, H., Goldfeld, K.S., Troxel, A.B., Daily, J.P., Wu, Yinxiang, dkk., 2022. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial. *JAMA Internal Medicine*, **182**: 115–126.
- Parasher, A., 2021. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. *Postgraduate Medical Journal*, **97**: 312–320.
- Pradhan, A. dan Olsson, P.-E., 2020. Sex differences in severity and mortality from COVID-19: are males more vulnerable? *Biology of Sex Differences*, **11**: 53.
- Pranata, R., Lim, M.A., Yonas, E., Vania, R., Lukito, A.A., dan Siswanto, B.B., 2020. 'Body mass index and outcome in patients with COVID-19: A doseresponse meta-analysis | Elsevier Enhanced Reader', URL: <https://reader.elsevier.com/reader/sd/pii/S1262363620300975?token=80A2C845180EB4B94D2DF9DCCE91A454ACFAE39E4CCFFC9559DE8E208179CC7ECD35F2D848CFCEE807D9D0ACA8C7F76&originRegion=eu-west-1&originCreation=20220818042138> (diakses tanggal 18/8/2022).
- Priya, S., Selva Meena, M., Sangumani, J., Rathinam, P., Brinda Priyadharshini, C., dan Vijay Anand, V., 2021. “Factors influencing the outcome of COVID-19 patients admitted in a tertiary care hospital, Madurai.- a cross-sectional study.” *Clinical Epidemiology and Global Health*, **10**: 100705.
- Rauf, A., Abu-Izneid, T., Olatunde, A., Ahmed Khalil, A., Alhumaydhi, F.A., Tufail, T., dkk., 2020. COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. *International Journal of Environmental Research and Public Health*, **17**: 8155.
- Sanders, J.M., Monogue, M.L., Jodlowski, T.Z., dan Cutrell, J.B., 2020. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*, **323**: 1824–1836.
- Satriyani, N., 2022. Perbandingan Efektivitas dan Keamanan Terapi Antiviral Favipiravir dan Remdesivir pada Pasien COVID-19 di RSUP Dr. Sardjito Yogyakarta.

- Satriyani, N., Rahmawati, F., dan Andayani, T.M., 2023. Perbandingan Angka Kematian Terapi Antiviral Favipiravir dan Remdesivir pada Pasien COVID-19 Di RSUP Dr. Sardjito Yogyakarta. *JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)*, **12**: 223–233.
- Scroggs, S.L.P., Offerdahl, D.K., Flather, D.P., Morris, C.N., Kendall, B.L., Broeckel, R.M., dkk., 2021. Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV. *Viruses*, **13**: 8.
- Seligman, W.H., Fialho, L., Sillett, N., Nielsen, C., Baloch, F.M., Collis, P., dkk., 2021. Which outcomes are most important to measure in patients with COVID-19 and how and when should these be measured? Development of an international standard set of outcomes measures for clinical use in patients with COVID-19: a report of the International Consortium for Health Outcomes Measurement (ICHOM) COVID-19 Working Group. *BMJ open*, **11**: e051065.
- Shinkai, M., Tsushima, K., Tanaka, S., Hagiwara, E., Tarumoto, N., Kawada, I., dkk., 2021. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. *Infectious Diseases and Therapy*, **10**: 2489–2509.
- Thapa, B., Pathak, S.B., Jha, N., Sijapati, M.J., dan Shankar, P.R., 2022. Antibiotics Use in Hospitalised COVID-19 Patients in a Tertiary Care Centre: A Descriptive Cross-sectional Study. *JNMA: Journal of the Nepal Medical Association*, **60**: 625–630.
- Udwadia, Z.F., Singh, P., Barkate, H., Patil, S., Rangwala, S., Pendse, A., dkk., 2021. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. *International Journal of Infectious Diseases*, **103**: 62–71.
- Vegivinti, C.T.R., Evanson, K.W., Lyons, H., Akosman, I., Barrett, A., Hardy, N., dkk., 2022. Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials. *BMC Infectious Diseases*, **22**: 107.
- Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., dkk., 2020. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA*, **323**: 1061–1069.
- Wang, J., Yang, W., Chen, P., Guo, J., Liu, R., Wen, P., dkk., 2021. The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis. *PLOS ONE*, **16**: e0249481.
- Wang, X., Guo, X., Xin, Q., Pan, Y., Hu, Y., Li, J., dkk., 2020. Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, ciae721.
- Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., dkk., 2020. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet (London, England)*, **395**: 1569–1578.

- WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection, 2020. A minimal common outcome measure set for COVID-19 clinical research. *The Lancet. Infectious Diseases*, **20**: e192–e197.
- Worldometer, 2022. 'COVID Live - Coronavirus Statistics - Worldometer', . URL: <https://www.worldometers.info/coronavirus/> (diakses tanggal 9/2/2022).
- Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., dkk., 2020. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *International Journal of Infectious Diseases*, **94**: 91–95.
- Yu, B., Li, X., Chen, J., Ouyang, M., Zhang, H., Zhao, X., dkk., 2020. Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis. *Journal of Thrombosis and Thrombolysis*, **50**: 548–557.
- Zaki, N., Alashwal, H., dan Ibrahim, S., 2020. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review. *Diabetes & Metabolic Syndrome*, **14**: 1133–1142.
- Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., dkk., 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*, **395**: 1054–1062.
- Zhu, L., She, Z.-G., Cheng, X., Qin, J.-J., Zhang, X.-J., Cai, J., dkk., 2020. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. *Cell Metabolism*, **31**: 1068-1077.e3.